UNICREDIT BANK/CALL/ROCHE GS/320/0.1/18.12.24 Share Price

Warrant

DE000HC7P3Z2

Real-time BOERSE MUENCHEN 12:45:48 28/06/2024 BST
0.15 EUR 0.00% Intraday chart for UNICREDIT BANK/CALL/ROCHE GS/320/0.1/18.12.24
Current month+111.27%
1 month+167.86%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
28/06/24 0.15 0.00%
27/06/24 0.15 0.00%
26/06/24 0.15 -11.76%
25/06/24 0.17 0.00%
24/06/24 0.17 0.00%

Real-time BOERSE MUENCHEN

Last update June 28, 2024 at 12:45 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer UniCredit UniCredit
WKN HC7P3Z
ISINDE000HC7P3Z2
Date issued 26/06/2023
Strike 320 CHF
Maturity 18/12/2024 (173 Days)
Parity 10 : 1
Emission price 1
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.95
Lowest since issue 0.001
Delta0.08x
Omega 14.64
Premium28.1x
Gearing179.61x
Moneyness 0.7841
Difference Strike 69.35 CHF
Difference Strike %+21.67%
Spread 0.03
Spread %18.75%
Theoretical value 0.1450
Implied Volatility 23.27 %
Total Loss Probability 94.02 %
Intrinsic value 0.000000
Present value 0.1450
Break even 321.40 €
Theta-0.01x
Vega0.03x
Rho0.01x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250.4 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.04%
Consensus